KYTX
Kyverna Therapeutics Inc.

965
Mkt Cap
$414.76M
Volume
583,825.00
52W High
$13.67
52W Low
$1.78
PE Ratio
-1.95
KYTX Fundamentals
Price
$7.26
Prev Close
$7.36
Open
$7.40
50D MA
$8.45
Beta
1.92
Avg. Volume
990,220.05
EPS (Annual)
-$3.33
P/B
2.09
Rev/Employee
$0.00
$134.37
Loading...
Loading...
News
all
press releases
Wall Street Zen Downgrades Kyverna Therapeutics (NASDAQ:KYTX) to Sell
Wall Street Zen lowered Kyverna Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·8h ago
News Placeholder
More News
News Placeholder
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Average Rating of "Moderate Buy" by Analysts
Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the five analysts that are covering the stock, Marketbeat.com reports...
MarketBeat·19d ago
News Placeholder
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to "Hold" at Wall Street Zen
Wall Street Zen raised shares of Kyverna Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday...
MarketBeat·1mo ago
News Placeholder
Kyverna Therapeutics (NASDAQ:KYTX) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen cut Kyverna Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·1mo ago
News Placeholder
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of "Moderate Buy" by Analysts
Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five research firms that are presently covering the company...
MarketBeat·1mo ago
News Placeholder
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why
KYTX's shares surge after positive phase II data showed its CAR T miv-cel delivered major mobility gains in stiff person syndrome.
Zacks·2mo ago
News Placeholder
Kyverna Therapeutics (NASDAQ:KYTX) Major Shareholder Biopartners Opportuni Westlake Buys 133,333 Shares
Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) major shareholder Biopartners Opportuni Westlake purchased 133,333 shares of the firm's stock in a transaction dated Thursday, December...
MarketBeat·2mo ago
News Placeholder
Kyverna Therapeutics (NASDAQ:KYTX) Major Shareholder Biopartners Opportuni Westlake Purchases 133,333 Shares
Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) major shareholder Biopartners Opportuni Westlake acquired 133,333 shares of Kyverna Therapeutics stock in a transaction that occurred on...
MarketBeat·2mo ago
News Placeholder
Beth Seidenberg Purchases 133,333 Shares of Kyverna Therapeutics (NASDAQ:KYTX) Stock
Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) Director Beth Seidenberg purchased 133,333 shares of the firm's stock in a transaction on Thursday, December 18th. The stock was acquired at...
MarketBeat·2mo ago
News Placeholder
KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data
Kyverna Therapeutics shares jump 23% after a registrational phase II study of miv-cel meets primary and all secondary efficacy goals for treating stiff person syndrome.
Zacks·2mo ago
<
1
2
...
>

Latest KYTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.